scPharmaceuticals Inc. (SCPH) Stock
scPharmaceuticals Inc.
Company profile
scPharmaceuticals reported revenue of $36.33 million for fiscal year 2024, up 167.3% from fiscal year 2023. In Q2 2025 (the quarter ended June 30, 2025) revenue was $16.04 million, up 99.2% from a year before. In Q2 2025 it reported a net loss of $18.02 million, against a net loss of $17.09 million a year earlier.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss widened from $54.81 million in fiscal year 2023 to $85.15 million in fiscal year 2024.
- Its average diluted share count rose 15.6% in fiscal year 2024, from 38.5 million to 44.5 million shares.
- Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2024.
In the news
- MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV, ARIS, SCPH on Behalf of Shareholders
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – GTLS, SCPH, VTLE, and VRNT
- Unusual volume stocks in Friday's session
How much revenue does scPharmaceuticals make?
scPharmaceuticals reported $36.33 million in revenue for fiscal year 2024, up 167.3% from $13.59 million in fiscal year 2023. In Q2 2025 revenue was $16.04 million.
What companies are similar to scPharmaceuticals?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Kalbe Farma Tbk. (KLBF.JK), Alteogen Inc. (196170.KQ), Chugai Pharmaceutical Co., Ltd. (4519.T), DHG Pharmaceutical Joint Stock Company (DHG.VN).
Has scPharmaceuticals made a profit in recent years?
Net income by fiscal year: FY2020, a loss of $32.21 million; FY2021, a loss of $28.03 million; FY2022, a loss of $36.84 million; FY2023, a loss of $54.81 million; FY2024, a loss of $85.15 million. It reported a net loss in each of these 5 years.
How has scPharmaceuticals' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, $0; FY2021, $0; FY2022, $0; FY2023, $13.59 million; FY2024, $36.33 million.
Data as of .
How to cite: DataPorium, “scPharmaceuticals Inc. (SCPH)”, data as of Jun 30, 2025, https://dataporium.tech/stocks/SCPH